WO2007116129A1 - A universal labeling system - Google Patents
A universal labeling system Download PDFInfo
- Publication number
- WO2007116129A1 WO2007116129A1 PCT/FI2007/050192 FI2007050192W WO2007116129A1 WO 2007116129 A1 WO2007116129 A1 WO 2007116129A1 FI 2007050192 W FI2007050192 W FI 2007050192W WO 2007116129 A1 WO2007116129 A1 WO 2007116129A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- template
- oligonucleotide
- terminus
- synthetic
- target nucleotide
- Prior art date
Links
- 238000002372 labelling Methods 0.000 title claims abstract description 15
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 70
- 239000002773 nucleotide Substances 0.000 claims abstract description 30
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000000295 complement effect Effects 0.000 claims abstract description 17
- 238000009396 hybridization Methods 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims abstract description 6
- 108090000790 Enzymes Proteins 0.000 claims abstract description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 10
- 239000013522 chelant Substances 0.000 claims description 8
- 229930024421 Adenine Natural products 0.000 claims description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 7
- 229960000643 adenine Drugs 0.000 claims description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 5
- 150000002602 lanthanoids Chemical class 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 229940035893 uracil Drugs 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 4
- 229910052693 Europium Inorganic materials 0.000 claims description 4
- 229910052772 Samarium Inorganic materials 0.000 claims description 4
- 229910052771 Terbium Inorganic materials 0.000 claims description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 4
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 4
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims description 4
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 claims description 3
- 229940104302 cytosine Drugs 0.000 claims description 3
- 150000004713 phosphodiesters Chemical class 0.000 claims description 3
- 238000002600 positron emission tomography Methods 0.000 claims description 3
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 claims description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 2
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical group [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims description 2
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 2
- 229940006110 gallium-67 Drugs 0.000 claims description 2
- 229940055742 indium-111 Drugs 0.000 claims description 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000008298 phosphoramidates Chemical class 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims description 2
- 229940104230 thymidine Drugs 0.000 claims description 2
- 239000002585 base Substances 0.000 description 26
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- -1 nucleoside triphosphates Chemical class 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000035657 Abasia Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
Definitions
- This invention relates to a novel method for labeling of target nucleotide strands, such as DNA and RNA.
- Oligonucleotides can be labeled either chemically or enzy- matically.
- the chemical approach includes often preparation of modified building blocks, and their subsequent insertion to synthetic oligonucleotides during oligonucleotide synthesis [Beaucage, S. L., Iyer, P.P., 1993, Tetrahedron, 49, 1859, US 6,949,639, US 09/985,454].
- the oligonucleotide or natural DNA or RNA can be transformed by bisulfite-catalyzed transamination of cytosine residues [Hayatsu, H., 1976, Biochemistry, 15, 2677, Draper, D.
- dNTPs deoxyribonucleotide 5 ' -triphosphates
- Organic dyes as label molecules suffer from commonly known drawbacks such as Raman scattering, concentration quenching and low water solubility. This is a major problem when these types of labels are statistically introduced in the nucleophilic sites of large bioactive molecules. In the worst case the labeled biomolecule has only a limited water solubility, totally unnatural three dimensional structure and no fluorescence properties derived from the label. Fortunately, several of these problems can be avoided by using lanthanide(lll) chelates as the labels. These molecules have several unique properties such as strong long-decay time luminescence, large Stokes shift and very sharp emission lines.
- stabile chelates composed of derivatives of pyridines [US 4,920,195; US 4,801 ,722; US 4,761 ,481 ; PCT/FI91 /00373; US 4,459,186; EP A-0770610; Remuinan et al, J. Chem. Soc. Perkin Trans 2, 1993, 1099], bipyridines [US 5,216,134], terpyridines [US 4,859,777; US 5,202,423; US 5,324,825] or various phenolic compounds [US 4,670,572; US 4,794,191 ; ltal Pat. 42508 A789] as the energy mediating groups and polycar- boxylic acids as chelating parts.
- Universal base analogues of nucleosides are designed to form base pairs with each of the natural DNA/RNA bases with little discrimination between them. Numerous such analogues have been synthesized and their applicability as biochemical toos have been investigated [Loakes, D., 2001 , Nucleic Acids Res., 29, 2437]. Universal bases must exhibit the ability to replace any of the five normal nucleobases without significantly affecting either melting behaviour of duplexes or the normal activities of the modified oligon u- cleotide. 3-Nitropyrrole [Nichols, R., Andrews, P. C, Zhang, P., Bergstom, D. E., 1994, Nature, 369, 492, Bergstrom, D.
- Oligonucleotide ligation assays useful for determining of mutations, for example, have been described in the art (US 6,506,594; WO 02/22883; Chackravarty et al., Thromb Haemost 1997; 78:1234-6).
- two nucleotide probes one immobilized and the other one labeled, where the probes are supposed to be complementary to a target oligonucleotide strand to be studied, are contacted with said target oligonucleotide. Ligation between the two probes occurs if the target oligonucleotide is complementary to the probes and thus able capable of binding the probes.
- the main object of the present invention is to provide a universal method for the labeling of nucleotide strands, such as DNA and RNA. Accordingly the method according to the invention comprises the steps of bringing into a contact with each other
- the invention concerns a composition useful in a method for labeling of a target nucleotide strand, comprising the components
- the invention concerns a capture oligonucleotide, useful for the removal of the template as defined above from the reaction mixture after completed ligation, said capture oligonucleotide having a sequence complementary to a target sequence in the template.
- the oligonucleotide label can be used in the labeling of all target molecules.
- the oligonucletide label can be synthesized in large scale using standard phosphoramidite chemistry. The labeling can be performed either in solution or on solid phase using commonly employed well documented procedures.
- the stability of the oligonucleotide label can be enhanced by modifying the phosphodiester backbone or by using non- nucleosidic labeling reactants.
- the template is constructed from natural bases complementary to the 3 ' -terminus of the oligonucleotide label and universal bases for hybridization with the target molecule, synthesis of only a single template oligonucleotide is required.
- target nucleotide strand shall mean an oligo- or polynucleotide to be labeled.
- the term shall be understood to cover natural as well as synthetic nucleotides.
- Non-restricting examples can be mentioned DNA and RNA nucleotides, ribozymes, siRNA:s and antisense strands.
- label refers especially to a detectable label, but the term shall also be understood to cover any other useful group, such as groups useful for immobilizing the target nucleotide strand to a solid support.
- Natural nucleobase shall be understood to mean adenine, thymine, uracil, cytosine or guanine.
- a linker which is formed from one to ten moieties, each moiety being selected from the group consisting of phenyl, alkyl containing 1 -12 carbon atoms
- the label is an organic dye, a spin label, biotin, or a luminescent or non-luminescent lantha- nide chelate or a chelate suitable for positron emission tomography or single photon emission computed tomography.
- the metal is gallium-67, gallium-68, indium-111 , technetium-98m, europium, terbium, samarium, gadolinium or dysprosium.
- the linker is covalently attached to N3 of uracil or N3 of thymidine, C5 of cytosine or C5 of uracil, N6 of adenine, C8 of adenine, 06 of guanine, C7 of deazaadenine, C7- of deazaguanine or C6 of adenine.
- the labeled oligonucleotide is constructed from natural phosphodiester linkages, phos- phoramidates, phosphoromonothioates or -dithioates.
- the labeled oligonucleotide has natural DNA bases at its 3 ' -terminus complementary to the 5 ' -terminus of the synthetic oligonucleotide template.
- the synthetic oligonucleotide template is preferably constructed from natural DNA bases at its 5 ' -terminus complementary to the natural DNA bases at the 3 ' -terminus of the labeled oligonucleotide, and universal DNA bases for hybridization with the target molecule.
- the universal bases are selected from hypoxantine, 3-nitropyrrole or 5-nitroindole.
- the number of labels, number of natural bases in the labeled oligonucleotide and template, and the number of universal bases in the template is judged according the demands of the application.
- the number of natural nucleobases in the synthetic labeled oligonucleotide is in the range of 10-20, and the and the number of natural bases in the template is at least the same as the number of natural nucleobases in the synthetic labeled oligonucleotide.
- the template oligonucleotide is preferably removed from the reaction mixture after completed ligation by a capture oligonucleotide having a sequence complementary to a target sequence in the template.
- a target sequence is, for example, the strand of natural bases in the template.
- the capture oligonucleotide is immobilized to a solid and is added to the reaction mixture after completion of the ligation reaction.
- the labeled oligonucleotide is allowed to hybridize with the template oligonucleotide in the presence of the target molecule and the enzyme (e.g. ligase).
- the enzyme e.g. ligase
- the order of addition of these reagents is not critical.
- the template oligonucleotide is removed by an excess of a capture oligonucleotide has a sequence complementary to a sequence in the template oligonucleotide.
- the capture oli- gonucleotide can be bound to a solid matrix. If desired, the template oligonucleotide can be released by increasing the temperature and reused.
- the number of the natural bases at the 3 ' -terminus of the labeled oligonucleotide and at the 5 ' -terminus of the template oligonucleotide depends on the structure of nucleobases. Accordingly, in order to form a stabile duplex at room temperature, ca 12 CG pairs or 15 AT pairs is needed.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention concerns a method for labeling of a target nucleotide strand. The following components are brought into a contact with each other: a) a synthetic labeled oligonucleotide having one or more lables at its 5'-terminus and a pretetermined number of natural nucleobases, sufficient for targetting to a template at its 3'-terminus; b) a synthetic oligonucleotide template having a sufficient number of natural nucleobases at its 5'-terminus complementary to the natural bases of the said synthetic labeled oligonucleotide, and a number of universal bases at its 3'-terminus required for hybridization with the target nucleotide strand; c) the target nucleotide strand; and d) an enzyme capable of connecting the target nucleotide to the synthetic labeled oligonucleotide, positioned in relation to the target nucleotide strand with the aid of the template.
Description
A UNIVERSAL LABELING SYSTEM
FIELD OF THE INVENTION
[0001] This invention relates to a novel method for labeling of target nucleotide strands, such as DNA and RNA.
BACKGROUND OF THE INVENTION
[0002] The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.
[0003] Oligonucleotides can be labeled either chemically or enzy- matically. The chemical approach includes often preparation of modified building blocks, and their subsequent insertion to synthetic oligonucleotides during oligonucleotide synthesis [Beaucage, S. L., Iyer, P.P., 1993, Tetrahedron, 49, 1859, US 6,949,639, US 09/985,454]. Alternatively, the oligonucleotide or natural DNA or RNA can be transformed by bisulfite-catalyzed transamination of cytosine residues [Hayatsu, H., 1976, Biochemistry, 15, 2677, Draper, D. E., Gold, L., 1980, Biochemistry, 19, 1774, Molander, J., Hurskainen, P., Hovinen, J., Lahti, M., Lδnnberg, H., 1993, Bioconjugate Chem., 4, 362, Adarichev, V.A., Kalachnikov, S. M., Kiseliova, A.V., Dymshits, G. M., 1998, Bioconjugate Chem., 9, 651], by electrophilic substitution of C8 of guanine residues [Tchen, P., Fuchs, R.P.P., Sage, E., Leng, M., 1984, PNAS, 81 , 3466] or by using label molecules tethered to platinum, which coordinates at N7 of guanine residues [US 5985566]. The enzymatic approach consists of preparation of nucleoside triphosphates derivatized with appropriate labels, and their incorporation into DNA by a polymerase reaction [US 2004214221].
[0004] All the above mentioned methods have their drawbacks. Attachment of linkers or labels to critical positions of DNA weaken hybridization properties of the oligomer. Although platinum predominantly coordinates at N7 of guanine residues, the reactivity of the platinated label is dependent on the base sequence of the target molecule as well as on the label attached. Furthermore, not only do N7 of guanine residues react but also other bases such
Lippert B., 1989, Progr. Inorg. Chem., 37, 1 , Lippert, B., Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug/; Ed. B. Lippert, Wiley-VCH, 1999., Perspectives on Bioinorganic Chemistry, Vol. 4, Eds R. W. Hay, J. R. Dilworth and K. B. Nolan, JAI Press, 1999]. Although coordination of the platinum label at N7 of guanine allows formation of natural Watson-Crick base pairs, the bulky substituents definitely change the three dimensional structure of the oligomer, especially in the cases where the label attached is an organic chromophore with intercalating properties. Furthermore, it has been shown that in certain cases platinated oligonucleotides are extremely labile as soon as the platinated oligonucleotide is paired with its complementary strand [Anin, M. -F., Gaugheron, F; Leng, M, 1992, Nucleic Acids Res., 20, 4825]. This, in turn, results in the formation of abasic sites and loss of genetic information and the label.
[0005] The labeled 2'-deoxyribonucleotide 5'-triphosphates (dNTPs) ought to be almost as good substrates to DNA polymerases as normal dNTPs. Since DNA polymerases are very sensitive to structural changes of their substrates, the selection of methods to attach non-radioactive markers into dNTPs are rather limited. Furthermore, the enzymatic approach based on DNA polymerases requires the use of a primer and a template.
[0006] Organic dyes as label molecules suffer from commonly known drawbacks such as Raman scattering, concentration quenching and low water solubility. This is a major problem when these types of labels are statistically introduced in the nucleophilic sites of large bioactive molecules. In the worst case the labeled biomolecule has only a limited water solubility, totally unnatural three dimensional structure and no fluorescence properties derived from the label. Fortunately, several of these problems can be avoided by using lanthanide(lll) chelates as the labels. These molecules have several unique properties such as strong long-decay time luminescence, large Stokes shift and very sharp emission lines. Indeed, time resolved fluorimetric assays based on lanthanide chelates have found increasing applications in diagnostics, research and high throughput screening. The heterogenous DELFIA technique (EP 0139675 B1 ; US 4,808,541 ; EP 0298939 B1 ; US 6,127,529; US
4,565,790; WO 03/076939; Hemmila I., Dakubu, S., Mukkala, V.-M., Siitari, H., Lδvgren, T., 1984, Anal. Biochem. 137, 335; Fl Pat. Appl. 20065030) is applied in assays requiring exceptional sensitivity, robustness and multi-label approach. The development highly stable and luminescent lanthanide(lll) chelates (Hemmila, I.; Mukkala, V.-M. 2001 , Crit. Rev. Clin. Lab. Sci. 38, 441 ) has enabled the use of homogenous assay technologies based on time resolution. The different photochemical properties of europium, terbium, dysprosium and samarium chelates enable development even multiparametric homogenous assays. Accordingly, a number of attempts have been made to develop new highly luminescent chelate labels suitable for time-resolved fluorometric applications. These include e.g. stabile chelates composed of derivatives of pyridines [US 4,920,195; US 4,801 ,722; US 4,761 ,481 ; PCT/FI91 /00373; US 4,459,186; EP A-0770610; Remuinan et al, J. Chem. Soc. Perkin Trans 2, 1993, 1099], bipyridines [US 5,216,134], terpyridines [US 4,859,777; US 5,202,423; US 5,324,825] or various phenolic compounds [US 4,670,572; US 4,794,191 ; ltal Pat. 42508 A789] as the energy mediating groups and polycar- boxylic acids as chelating parts. In addition, various dicarboxylate derivatives [US 5,032,677; US 5,055,578; US 4,772,563] macrocyclic cryptates [US 4,927,923; WO 93/5049; EP-A-493745] and macrocyclic Schiff bases [EP-A- 369000] have been disclosed. Recently, development of neutral, highly luminescent stable europium, terbium, samarium and dysprosium chelates based on azamacrocycles has been disclosed [US Pat. Appl.10/928, 143; US Pat. Appl. 11/004,061]. By changing the nature of the chelating metal these type of molecules can be used also in positron emission tomography, single photon emission tomography and magnetic resonance imaging.
[0007] Universal base analogues of nucleosides are designed to form base pairs with each of the natural DNA/RNA bases with little discrimination between them. Numerous such analogues have been synthesized and their applicability as biochemical toos have been investigated [Loakes, D., 2001 , Nucleic Acids Res., 29, 2437]. Universal bases must exhibit the ability to replace any of the five normal nucleobases without significantly affecting either melting behaviour of duplexes or the normal activities of the modified oligon u-
cleotide. 3-Nitropyrrole [Nichols, R., Andrews, P. C, Zhang, P., Bergstom, D. E., 1994, Nature, 369, 492, Bergstrom, D. E., Zhang, P., Toma, P. H., Andrews, P.C., Nichols, R., 1995, J. Am. Chem. Soc, 117, 1201] or 5-nitroindole [Loakes, D., Brown, D. M, 1994, Nucleic Acids Res., 22, 4039] as well as the naturally occurring base, hypoxantine [Ohtsuka, E., Matsuki, S., Ikehara, M., Takahashi, Y., Matsubara, K., 1985, J. Biol. Chem., 260, 2605, Takahashi, Y., Kato, K., Hayashizaki, Y., Wakabayashi, T., Ohtsuka, E., Matsuki, S., Ikehara, M., Matsubara, K., 1985, PNAS, 82, 1931], are among the most commonly used. Phosphoramidites derived from these and several other universal bases are currently commercially available.
[0008] Oligonucleotide ligation assays, useful for determining of mutations, for example, have been described in the art (US 6,506,594; WO 02/22883; Chackravarty et al., Thromb Haemost 1997; 78:1234-6). Here two nucleotide probes, one immobilized and the other one labeled, where the probes are supposed to be complementary to a target oligonucleotide strand to be studied, are contacted with said target oligonucleotide. Ligation between the two probes occurs if the target oligonucleotide is complementary to the probes and thus able capable of binding the probes.
[0009] However, use a template oligonucleotide, bearing a number of natural bases and a number of universal bases, to enable introduction of a label into any target oligonucleotide strand, has not been described so far.
SUMMARY OF THE INVENTION
[0010] The main object of the present invention is to provide a universal method for the labeling of nucleotide strands, such as DNA and RNA. Accordingly the method according to the invention comprises the steps of bringing into a contact with each other
[0011] a) a synthetic labeled oligonucleotide having one or more lables at its 5'-terminus and a pretetermined number of natural nucleobases, sufficient for targetting to a template at its 3'-terminus;
[0012] b) a synthetic oligonucleotide template having a sufficient number of natural nucleobases at its 5'-terminus complementary to the natural
bases of the said synthetic labeled oligonucleotide, and a number of universal bases at its 3'-terminus required for hybridization with the target nucleotide strand;
[0013] c) the target nucleotide strand; and
[0014] d) an enzyme capable of connecting the target nucleotide to the synthetic labeled oligonucleotide, positioned in relation to the target nucleotide strand with the aid of the template.
[0015] Furthermore, the invention concerns a composition useful in a method for labeling of a target nucleotide strand, comprising the components
[0016] a) a synthetic labeled oligonucleotide having one or more lables at its 5'-terminus and a pretetermined number of natural nucleobases, sufficient for targetting to a template at its 3'-terminus, and
[0017] b) a synthetic oligonucleotide template having a sufficient number of natural nucleobases at its 5'-terminus complementary to the natural bases of the said synthetic labeled oligonucleotide, and a number of universal bases at its 3'-terminus required for hybridization with the target nucleotide strand, and optionally
[0018] c) an enzyme capable of connecting the target nucleotide to the synthetic labeled oligonucleotide, positioned in relation to the target nucleotide strand with the aid of the template.
[0019] Still further, the invention concerns a capture oligonucleotide, useful for the removal of the template as defined above from the reaction mixture after completed ligation, said capture oligonucleotide having a sequence complementary to a target sequence in the template.
[0020] Major advantages of the invention:
[0021] The new approach according to the present invention has the following advantages:
[0022] (i) The target molecule remains intact, and hence its hydridi- zation properties are not changed upon labeling.
[0023] (ii) The oligonucleotide label can be used in the labeling of all target molecules.
[0024] (iii)The oligonucletide label can be synthesized in large scale using standard phosphoramidite chemistry. The labeling can be performed either in solution or on solid phase using commonly employed well documented procedures.
[0025] (iv)lf required, the stability of the oligonucleotide label can be enhanced by modifying the phosphodiester backbone or by using non- nucleosidic labeling reactants.
[0026] (v) The nature of the label can be tailored according to the application.
[0027] (vi)Since the template is constructed from natural bases complementary to the 3'-terminus of the oligonucleotide label and universal bases for hybridization with the target molecule, synthesis of only a single template oligonucleotide is required.
DETAILED DESCRIPTION OF THE INVENTION [0028] Definitions:
[0029] The term "target nucleotide strand" shall mean an oligo- or polynucleotide to be labeled. The term shall be understood to cover natural as well as synthetic nucleotides. As non-restricting examples can be mentioned DNA and RNA nucleotides, ribozymes, siRNA:s and antisense strands.
[0030] The term "label" refers especially to a detectable label, but the term shall also be understood to cover any other useful group, such as groups useful for immobilizing the target nucleotide strand to a solid support.
[0031] "Natural nucleobase" shall be understood to mean adenine, thymine, uracil, cytosine or guanine.
[0032] According to a preferable embodiment, the label is linked to a nucleobase via a linker which is formed from one to ten moieties, each moiety being selected from the group consisting of phenyl, alkyl containing 1 -12 carbon atoms, ethynediyl (-C≡C-), ethylenediyl (-C=C-); ether (-O-), thioether (- S-), amide (-CO-NH- and -NH-CO- and -CO-NR2 and -NR2-CO-), carbonyl (- CO-), ester (-COO- and -OOC-), disulfide (-SS-), diaza (-N=N-) or a tertiary
amine (-NR -), where R represents an alkyl containing less than 5 carbon atoms.
[0033] According to another preferable embodiment, the label is an organic dye, a spin label, biotin, or a luminescent or non-luminescent lantha- nide chelate or a chelate suitable for positron emission tomography or single photon emission computed tomography.
[0034] According to a further preferable embodiment, the metal is gallium-67, gallium-68, indium-111 , technetium-98m, europium, terbium, samarium, gadolinium or dysprosium.
[0035] According to a further preferable embodiment, the linker is covalently attached to N3 of uracil or N3 of thymidine, C5 of cytosine or C5 of uracil, N6 of adenine, C8 of adenine, 06 of guanine, C7 of deazaadenine, C7- of deazaguanine or C6 of adenine.
[0036] According to a further preferable embodiment, the labeled oligonucleotide is constructed from natural phosphodiester linkages, phos- phoramidates, phosphoromonothioates or -dithioates.
[0037] Preferably, the labeled oligonucleotide has natural DNA bases at its 3'-terminus complementary to the 5'-terminus of the synthetic oligonucleotide template.
[0038] The synthetic oligonucleotide template is preferably constructed from natural DNA bases at its 5'-terminus complementary to the natural DNA bases at the 3'-terminus of the labeled oligonucleotide, and universal DNA bases for hybridization with the target molecule.
[0039] According to a preferable embodiment, the universal bases are selected from hypoxantine, 3-nitropyrrole or 5-nitroindole.
[0040] According to a preferable embodiment, the number of labels, number of natural bases in the labeled oligonucleotide and template, and the number of universal bases in the template is judged according the demands of the application.
[0041] Preferably, the number of natural nucleobases in the synthetic labeled oligonucleotide is in the range of 10-20, and the and the number
of natural bases in the template is at least the same as the number of natural nucleobases in the synthetic labeled oligonucleotide.
[0042] The template oligonucleotide is preferably removed from the reaction mixture after completed ligation by a capture oligonucleotide having a sequence complementary to a target sequence in the template. Such a target sequence is, for example, the strand of natural bases in the template.
[0043] According to a preferable embodiment, the capture oligonucleotide is immobilized to a solid and is added to the reaction mixture after completion of the ligation reaction.
SCHEMATIC PRESENTATION OF THE LABELING PROCEDURE
[0044] The scheme below illustrates the principle of the present labeling strategy.
O
N- A
X J
[0045] The labeling procedure is the following
[0046] 1. The labeled oligonucleotide is allowed to hybridize with the template oligonucleotide in the presence of the target molecule and the enzyme (e.g. ligase). The order of addition of these reagents is not critical.
[0047] 2. When the ligation is completed, the template oligonucleotide is removed by an excess of a capture oligonucleotide has a sequence complementary to a sequence in the template oligonucleotide. The capture oli-
gonucleotide can be bound to a solid matrix. If desired, the template oligonucleotide can be released by increasing the temperature and reused.
[0048] The number of the natural bases at the 3'-terminus of the labeled oligonucleotide and at the 5'-terminus of the template oligonucleotide depends on the structure of nucleobases. Accordingly, in order to form a stabile duplex at room temperature, ca 12 CG pairs or 15 AT pairs is needed.
Claims
Claims:
[0049] 1. Method for labeling of a target nucleotide strand, comprising the steps of bringing into a contact with each other
[0050] a) a synthetic labeled oligonucleotide having one or more lables at its 5'-terminus and a pretetermined number of natural nucleobases, sufficient for targetting to a template at its 3'-terminus;
[0051] b) a synthetic oligonucleotide template having a sufficient number of natural nucleobases at its 5'-terminus complementary to the natural bases of the said synthetic labeled oligonucleotide, and a number of universal bases at its 3'-terminus required for hybridization with the target nucleotide strand;
[0052] c) the target nucleotide strand; and
[0053] d) an enzyme capable of connecting the target nucleotide strand to the synthetic labeled oligonucleotide, positioned in relation to the target nucleotide strand with the aid of the template.
[0054] 2. The method according to claim 1 wherein the synthetic labeled oligonucleotide comprises a chain of one or more labeled nucleotides.
[0055] 3. The method according to claim 1 or 2, where the label is an organic dye, a spin label, biotin, or a metal chelate, which optionally is linked to the nucleobase via a linker which is formed from one to ten moieties, each moiety being selected from the group consisting of phenyl, alkyl containing 1-12 carbon atoms, ethynediyl (-C≡C-), ethylenediyl (-C=C-); ether (-O-), thioether (-S-), amide (-CO-NH- and -NH-CO- and -CO-NR2 and -NR2-CO-), carbonyl (-CO-), ester (-COO- and -OOC-), disulfide (-SS-), diaza (-N=N-) or a tertiary amine (-NR2-), where R2 represents an alkyl containing less than 5 carbon atoms.
[0056] 4. The method according to claim 3 where the metal chelate is a luminescent or non-luminescent lanthanide(lll) chelate of a chelate suitable for positron emission tomography or single photon emission computed tomography.
[0057] 5. The method according to claim 3 where the metal chelate is gallium-67, gallium-68, indium-111 , technetium-98m, europium, terbium, samarium, gadolinium or dysprosium.
[0058] 6. The method according to claim 3 where the linker is cova- lently attached to N3 of uracil or N3 of thymidine, C5 of cytosine or C5 of uracil, N6 of adenine, C8 of adenine, 06 of guanine, C7 of deazaadenine, C7- of deazaguanine or C6 of adenine.
[0059] 7. The method according to claim 1 where the labeled oligonucleotide is constructed from natural phosphodiester linkages, phosphora- midates, phosphoromonothioates or -dithioates.
[0060] 8. The method according to claim 1 , where the synthetic labeled oligonucleotide has natural DNA bases at its 3'-terminus complementary to the 5'-terminus of the synthetic oligonucleotide template.
[0061] 9. The method according to claim 1 where the universal bases are selected from hypoxantine, 3-nitropyrrole or 5-nitroindole.
[0062] 10. The method according to claim 1 where the number of labels, number of natural bases in the labeled oligonucleotide and template, and the number of universal bases in the template is judged according the demands of the application.
[0063] 11. The method according to claim 10 wherein the number of natural nucleobases in the synthetic labeled oligonucleotide is in the range of 10-20, and the and the number of natural bases in the template is at least the same as the number of natural nucleobases in the synthetic labeled oligonucleotide.
[0064] 12. The method according to claim 1 where the template oligonucleotide is removed form the reaction mixture after completed ligation by a capture oligonucleotide having a sequence complementary to a target sequence in the template.
[0065] 13. The method according to claim 12 where the capture oligonucleotide is immobilized to a solid matrix.
[0066] 14. A composition useful in a method for labeling of a target nucleotide strand comprising the components
[0067] a) a synthetic labeled oligonucleotide having one or more lables at its 5'-terminus and a pretetermined number of natural nucleobases, sufficient for targetting to a template at its 3'-terminus, and
[0068] b) a synthetic oligonucleotide template having a sufficient number of natural nucleobases at its 5'-terminus complementary to the natural bases of the said synthetic labeled oligonucleotide, and a number of universal bases at its 3'-terminus required for hybridization with the target nucleotide strand, and optionally
[0069] c) an enzyme capable of connecting the target nucleotide to the synthetic labeled oligonucleotide, positioned in relation to the target nucleotide strand with the aid of the template.
[0070] 15. A capture oligonucleotide, useful for the removal of the template defined in claim 14 from the reaction mixture after completed ligation, said capture oligonucleotide having a sequence complementary to a target sequence in the template.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79055606P | 2006-04-10 | 2006-04-10 | |
US60/790,556 | 2006-04-10 | ||
FI20065228A FI20065228A0 (en) | 2006-04-10 | 2006-04-10 | A universal labeling system |
FI20065228 | 2006-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007116129A1 true WO2007116129A1 (en) | 2007-10-18 |
Family
ID=38580731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2007/050192 WO2007116129A1 (en) | 2006-04-10 | 2007-04-05 | A universal labeling system |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007116129A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1138689A1 (en) * | 2000-03-28 | 2001-10-04 | Roche Diagnostics GmbH | N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization |
US6506594B1 (en) * | 1999-03-19 | 2003-01-14 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
WO2003102228A1 (en) * | 2002-06-04 | 2003-12-11 | The Walter And Eliza Hall Institute Of Medical Research | A nucleic acid anchoring system comprising covalent linkage of an oligonucleotide to a solid support |
-
2007
- 2007-04-05 WO PCT/FI2007/050192 patent/WO2007116129A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506594B1 (en) * | 1999-03-19 | 2003-01-14 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
EP1138689A1 (en) * | 2000-03-28 | 2001-10-04 | Roche Diagnostics GmbH | N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization |
WO2003102228A1 (en) * | 2002-06-04 | 2003-12-11 | The Walter And Eliza Hall Institute Of Medical Research | A nucleic acid anchoring system comprising covalent linkage of an oligonucleotide to a solid support |
Non-Patent Citations (1)
Title |
---|
LOAKES D.: "Survey and Summary: The applications of universal DNA base analogues", NUCLEIC ACIDS RESEARCH, vol. 29, no. 12, 2001, pages 2437 - 2447 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6903206B1 (en) | Kits for amplifying target nucleic acid sequences using modified oligonucleotides | |
US6743905B2 (en) | Mobility-modified nucleobase polymers and methods of using same | |
US6902900B2 (en) | Nucleic acid probes and methods to detect and/or quantify nucleic acid analytes | |
US7495093B2 (en) | Amplification and detection method | |
CN101312941A (en) | Polynucleotide labelling reagent | |
CN101896491B (en) | fluorescent molecule | |
EP3401407A1 (en) | Nucleic acid probe, method for designing nucleic acid probe, and method for detecting target sequence | |
EP1177209B1 (en) | Compositions of solvents and high concentrations of nucleic acid analogs | |
WO2007116129A1 (en) | A universal labeling system | |
EP1308452B1 (en) | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | |
JP5114705B2 (en) | Bipyridine-modified nucleoside or nucleotide and method for detecting methylcytosine using the same | |
Hurskainen | Nucleic acid labelling employing lanthanide chelates | |
JP4779147B2 (en) | Nucleotide derivatives and uses thereof | |
JP4963015B2 (en) | Nucleotide derivatives and uses thereof | |
JP2007031389A6 (en) | Nucleotide derivatives and uses thereof | |
US7482444B2 (en) | Terminating substrates for DNA polymerases | |
US20040230047A1 (en) | Novel phosphorylation reagents for improved processes to convert terminal hydroxyl groups of oligonucleotides into phosphate monoesters | |
WO2007105623A1 (en) | Oligonucleotide-immobilized solid support |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07730679 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07730679 Country of ref document: EP Kind code of ref document: A1 |